글로벌 식도암 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

식도암 시장 분석

식도암 시장은 발병률 증가, 치료 옵션의 발전, 조기 발견에 대한 인식 증가에 힘입어 상당한 성장을 경험하고 있습니다. 이 시장은 표적 치료 및 면역 요법을 포함한 혁신적인 치료법의 강력한 파이프라인에 의해 뒷받침됩니다. 최근의 발전에는 FDA가 Opdivo(nivolumab)와 같은 신약을 승인하고, 진행성 식도 편평세포암에 Yervoy(ipilimumab)와 병용하는 것이 포함되며, 이는 개인화된 의학으로의 전환을 강조합니다. 또한 정부 이니셔티브와 연구 자금의 증가는 조기 발견 기술 개발을 강화하여 환자 결과를 개선하고 있습니다. 이 시장은 또한 완화 치료와 지지 치료에 대한 강조가 커지고 있으며, 이는 환자 관리에 대한 보다 전체론적인 접근 방식을 반영합니다. 또한 제약 회사와 연구 기관 간의 협력으로 효과적인 치료 방식의 개발이 가속화되어 식도암 시장은 향후 몇 년 동안 더 나은 관리와 치료 결과를 약속하는 역동적이고 빠르게 진화하는 분야가 되었습니다.

식도암 시장 규모

글로벌 식도암 시장 규모는 2023년에 13억 4천만 달러로 평가되었으며, 2031년까지 25억 7천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

식도암 시장 동향

“ 표적 치료의 사용 증가”

식도암 시장은 발병률 증가와 치료 옵션의 발전에 힘입어 상당한 성장을 목격하고 있습니다. 주목할 만한 추세 중 하나는 환자 결과를 개선하고 보다 개인화된 치료 접근 방식을 제공하는 표적 치료의 증가입니다. 예를 들어, 2022년 HER2 양성 식도암에 대한 트라스투주맙 데룩스테칸(Enhertu)의 승인은 치료 환경을 변화시켜 이전에 선택의 폭이 제한적이었던 환자에게 새로운 옵션을 제공했습니다. 이러한 치료법은 유망한 결과를 보였으며, 임상 시험에서 긍정적인 반응률을 나타내 생존율을 개선할 수 있는 잠재력을 반영했습니다. 또한 액체 생검 기술의 채택이 증가함에 따라 조기 발견과 치료 반응의 실시간 모니터링이 가능해져 환자 관리가 더욱 향상되고 있습니다. 식도암 시장은 이러한 혁신적인 치료 방식과 개인화된 의학에 대한 집중이 증가함에 따라 성장할 준비가 되었습니다.

보고 범위 및 식도암 시장 세분화

Esophageal Cancer Market Definition

Esophageal cancer is a type of cancer that originates in the esophagus, the long, hollow tube that connects the throat to the stomach. It occurs when cells in the esophagus undergo genetic mutations that lead to uncontrolled growth and division, forming tumors. There are two main types of esophageal cancer: adenocarcinoma, which usually develops in the lower part of the esophagus and is often associated with chronic acid reflux and Barrett's esophagus, and squamous cell carcinoma, which typically occurs in the upper and middle sections and is linked to factors such as smoking and heavy alcohol consumption. Esophageal cancer symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn.

Esophageal Cancer Market Dynamics

Drivers

• Increasing Incidence Rates of Esophageal Cancer

Increasing incidence rates of esophageal cancer are significantly influenced by rising prevalence of risk factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. The American Cancer Society reported that the incidence of esophageal cancer has nearly tripled in the last four decades, with an estimated 20,640 new cases diagnosed in the U.S. in 2023. Research indicates that obesity is a key contributor, with studies showing that individuals with a body mass index (BMI) over 30 have a twofold increased risk of developing esophageal adenocarcinoma compared to those with a normal weight. In addition, the prevalence of GERD, which affects approximately 20% of the U.S. population, further heightens the risk of esophageal cancer due to chronic inflammation and damage to the esophageal lining. Such alarming trends underscore the urgent need for effective treatment options and preventive strategies in managing esophageal cancer, ultimately driving the market expansion.

• Rising Healthcare Expenditure

Rising healthcare expenditure is a significant driver of growth in the esophageal cancer market, as patients increasingly seek advanced treatment options and comprehensive care. According to a report from the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending reached approximately USD 4.3 trillion in 2021, with oncology services accounting for a substantial portion of this expenditure. This trend reflects a growing investment in cancer research, treatment technologies, and patient care initiatives. Furthermore, with more hospitals and clinics adopting cutting-edge technologies such as robotic surgery and personalized treatment plans, patients are more such asly to receive timely and effective care for esophageal cancer. Such increased spending on healthcare enhances treatment accessibility and improves patient outcomes, further driving market growth.

Opportunities

• Growing Advancements in Treatment Options

Advancements in treatment options for esophageal cancer are significantly enhancing patient outcomes, particularly through innovations in immunotherapies and minimally invasive surgical techniques. For Instance, the development of nivolumab (Opdivo), an immune checkpoint inhibitor approved for esophageal squamous cell carcinoma improves overall survival rates. In addition, the adoption of minimally invasive techniques such as endoscopic submucosal dissection (ESD) allows for the removal of early-stage tumors with less trauma compared to traditional surgery, leading to quicker recovery times and reduced hospital stays. The integration of such advanced therapies expands treatment options for esophageal cancer patients and create opportunities for further market growth, as healthcare providers increasingly incorporate cutting-edge interventions to improve care quality and effectiveness.

• Growing Awareness of Symptoms and Risk Factors

Growing awareness of esophageal cancer symptoms and risk factors has significantly contributed to earlier diagnoses, enhancing treatment outcomes for patients. Initiatives aimed at educating the public about the risks associated with obesity, smoking, and gastroesophageal reflux disease (GERD) have been pivotal in this regard. In addition, advancements in diagnostic technologies, such as high-definition endoscopy and liquid biopsy, are enabling healthcare providers to detect esophageal cancer at more treatable stages. Liquid biopsy, which allows for the non-invasive analysis of circulating tumor DNA, has shown promise in identifying cancer recurrence earlier than traditional methods. Such developments facilitate timely intervention and contribute to improved survival rates, further emphasizing the importance of awareness and early detection in broadening opportunities for esophageal cancer market.

Restraints/Challenges

• High Treatment Cost

High treatment costs represent a significant barrier in the esophageal cancer market, particularly regarding advanced treatment options such as immunotherapies and targeted therapies. For instance, trastuzumab deruxtecan (Enhertu), a groundbreaking therapy for HER2-positive esophageal cancer, can be prohibitively expensive, placing immense strain on patients and healthcare systems, especially in countries with high out-of-pocket expenses for medications. This financial burden is particularly challenging for patients lacking comprehensive insurance coverage, as many may struggle to afford these innovative therapies. Consequently, the high costs associated with effective treatment options can limit access, potentially resulting in poorer health outcomes for those diagnosed with esophageal cancer.

• Delays in Regulatory Approvals

Regulatory hurdles significantly challenge the esophageal cancer market, as stringent requirements can delay the approval and market entry of new therapies. For example, navigating the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval processes can take several years, often prolonging the timeline for innovative treatments to reach patients. Such prolonged timeline can be particularly detrimental in oncology, where advancements are critical for improving patient outcomes, as patients with advanced disease may not have the luxury of waiting for new therapies, hindering the overall market expandion.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Esophageal Cancer Market Scope

The market is segmented on the basis of type, treatment type, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Esophageal Squamous-Cell Carcinoma
• Esophageal Adenocarcinoma
• Others

Treatment Type

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Esophageal Cancer Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment type, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific region leads the market, largely attributed to the rapid development of healthcare facilities that enhance access to essential services. A significant presence of generic manufacturers also supports market growth by providing affordable treatment options. Furthermore, increasing government initiatives and the establishment of specialist communities are driving advancements in healthcare delivery, contributing to the region's dominance in the market.

North America is anticipated to experience the most significant market growth, driven by its position as a global leader in research and development activities. The region benefits from a well-established regulatory approval framework that facilitates the introduction of new treatments. In addition, the rising incidence of esophageal cancer is fueling demand for innovative therapies and technologies, further contributing to market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Esophageal Cancer Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Esophageal Cancer Market Leaders Operating in the Market Are:

• Johnson & Johnson Services, Inc. (U.S.)
• Cipla (U.S.)
• Abbott (U.S.)
• AbbVie Inc.(미국)
• 머크 KGaA(독일)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 히크마 제약(영국)
• Amneal Pharmaceuticals LLC(미국)
• 파이저 주식회사(미국)
• Viatris Inc. (미국)
• 노바티스 AG(스위스)
• 브리스톨-마이어스 스퀴브 회사(미국)
• GSK plc (영국)
• Bayer AG(독일)
• 오츠카 아메리카 제약 주식회사(일본)
• 장쑤 헝루이 제약 주식회사(중국)

식도암 시장의 최신 동향

• 2024년 9월, 수술 중 암 조직을 탐지하기 위한 혁신적인 형광 유도 영상 기술을 만드는 데 전념하는 사설 회사인 Lumicell, Inc.는 국립보건원(NIH)의 국립암연구소(NCI)로부터 1단계 중소기업 혁신 연구(SBIR) 계약을 체결했다고 발표했습니다. 이 계약은 표준 임상 내시경 검사 중 전암성 병변과 초기 단계 식도선암(EAC)을 식별하기 위해 원적외선 형광 및 반사광 영상을 통합하는 새로운 유연한 내시경 플랫폼의 개발을 지원합니다.
• 2022년 5월, 미국 식품의약국(FDA)은 Bristol Myers Squibb에 두 가지 제품, 즉 정맥 주사용 Opdivo(nivolumab)와 Opdivo와 Yervoy(ipilimumab)의 조합에 대한 승인을 부여했습니다. 이는 진행성 또는 전이성 식도 편평세포암(ESCC)으로 진단받은 환자의 1차 치료제입니다.

SKU-53749